VarmX Raises €32 Million in Series B Financing to Develop Innovative Reversal Agent for the Treatment and Prevention of Severe Bleeding in Patients on Oral Anticoagulants
PRIVATEJul 08, 2020
Amount Raised
€32 Million
Round Type
Series B
Leiden
Description
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the completion of a €32 million Series B financing round.
Who to call at VarmX, and when
A new round usually means VarmX is about to hire and buy. The teams that reach out first get the meeting.
An alert the day VarmX raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at VarmX, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at VarmX. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
VarmX
Location
Leiden, South Holland, Netherlands
About
VarmX is a biotech company developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment VarmX raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Leiden